IDEAYA registers Phase 3 adjuvant trial of darovasertib plus crizotinib in uveal melanoma

This week's item concerns a newly posted Phase 3 trial from IDEAYA Biosciences.

• The trial, "A Randomized, Phase 3, Open-label Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma" (NCT07804186), is recruiting. It will enroll 450 participants¹ who have completed primary local therapy such as plaque brachytherapy, proton beam radiation, or enucleation, with median relapse-free survival as the primary outcome, measured as time to local recurrence or metastatic disease per RECIST v1.1¹. Participants are split between a treatment arm receiving darovasertib plus crizotinib¹ and an observation arm that will not receive darovasertib + crizotinib but will be observed and followed for disease recurrence and survival¹.